Jefferies analyst Andrew Tsai raised the price target on Alto Neuroscience (NYSE: ANRO) to $35.00 (from $25.00) while maintaining a Buy rating.

The analyst commented, "ANRO's precision psychiatry platform has several 2026-27 data readouts: (1) In Q1:26-end, ALTO-101 (PDE4 patch) has Phase II CIAS schizophrenia data that could show a strong correlation between EEG (efficacy biomarker) and cognition, (2) In mid-2026, ALTO-300 (oral agomelatine) has Phase IIb MDD depression data, (3) ALTO-100 (oral BDNF) has Phase IIb BPD depression data in H2:26, (4) ALTO-207 (oral dopamine combo) has Phase IIb adjunct TRD data in H2:27."